Co-Diagnostics Gains Tailwind from Federal Vector-Borne Disease Initiative

  • Executive Order 14433 signed September 29, 2026, prioritizes vector-borne disease detection, creating federal R&D programs for rapid diagnostics.
  • Co-Diagnostics' Vector Smart® platform targets pathogens including West Nile virus, Zika, dengue, and chikungunya, with 40 customers across 21 U.S. states.
  • Company secured first U.S. Air Force deployment in September 2026 and plans participation in four regional mosquito control conferences this fall.
  • Vector Smart assays underwent independent validation by a state public health laboratory, reinforcing market positioning.

The federal initiative on vector-borne disease detection aligns with Co-Diagnostics' strategic focus on decentralized molecular surveillance. With growing customer adoption and regulatory support, the company is well-positioned to capitalize on increased public health funding. The upcoming conferences and webinar will be key to solidifying partnerships and securing contracts under the new federal framework.

Regulatory Tailwinds
How federal funding and R&D programs will accelerate demand for Co-Diagnostics' Vector Smart platform.
Market Expansion
Whether Co-Diagnostics can sustain its growth trajectory beyond U.S. borders following its first international deployment.
Competitive Positioning
The pace at which competitors develop similar decentralized mosquito surveillance solutions.